- Gilead Sciences has concluded pricing negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for Lyvdelzi (seladelpar), bringing Canadians with primary biliary cholangitis (PBC) closer to a publicly funded treatment option.
- The agreement clears a key national pricing step, allowing participating provincial, territorial and federal drug plans to review Lyvdelzi for public formulary listing and determine reimbursement criteria.
- PBC is a progressive autoimmune liver disease that damages bile ducts and can lead to severe liver damage. The agreement marks a step toward expanding treatment access for this underserved patient community.
- Some public drug plans could begin reimbursing eligible patients as early as 2027, depending on jurisdictional decisions. Patients enrolled in Gilead’s Momentum Support Program will transition to public plans as coverage agreements are reached.
Takeaways:
Gilead’s pCPA agreement advances LYVDELZI toward broader Canadian access, strengthening its position in the PBC treatment market. Public reimbursement could reduce affordability barriers and expand uptake, but provincial formulary decisions, eligibility criteria, rollout timelines and differentiation from existing therapies will determine its commercial impact.
Source: CA Newswire
